NCT00679640CompletedNot Applicable
Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 450
- Locations
- 1
- Primary Endpoint
- Profile of patients treated with candesartan for heart failure
Study Overview
Brief Summary
The purpose of this study is to describe the way candesartan is used in heart failure treatment in France (treatment initiation and monitoring), treatment stops occurrence and reasons for and patients clinical evolution
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •outpatients to whom candesartan has been initiated for less than 30 days or during the consultation to treat heart failure
Exclusion Criteria
- •patients included in a clinical trial the last 30 days before consultation
- •patients unable to answer the questions for linguistic or cognitive reasons
- •patients who will be difficult to follow during the one year study
Arms & Interventions
1
Outpatients to whom candesartan has been initiated for less than 30 days or during the consultation to treat heart failure
Intervention: Candesartan (Drug)
Outcomes
Primary Outcomes
Profile of patients treated with candesartan for heart failure
Time Frame: At inclusion
Secondary Outcomes
- Percentage of patients taking correctly its treatment : indication, contraindication, drug titration, treatment monitoring(6 and 12 months after)
- Percentage of patients stopping its treatment and reasons why(12 months after)
- Percentage of hospitalisations due to heart failure and cardiovascular deaths(12 months after)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)Congestive Heart FailureNCT00634309AstraZeneca597
Completed
Phase 3
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)Congestive Heart FailureNCT00634712AstraZeneca734
Completed
Phase 3
Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)Congestive Heart FailureNCT00634400AstraZeneca6,268
Completed
Phase 3
Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.Heart FailureNCT00775840Takeda22
Completed
Not Applicable
Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months)HypertensionNCT02016183Takeda3,222
